Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).

Trial Profile

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2012 Planned end date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 25 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top